Common-Size Income Statement
Beginner level
Regeneron Pharmaceuticals Inc., common-size consolidated income statement
Based on: 10-K (filing date: 2021-02-08), 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09).
Income statement item | Description | The company |
---|---|---|
Income from operations | The net result for the period of deducting operating expenses from operating revenues. | Regeneron Pharmaceuticals Inc.’s income from operations as a percentage of revenues decreased from 2018 to 2019 but then increased from 2019 to 2020 exceeding 2018 level. |
Income before income taxes | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. | Regeneron Pharmaceuticals Inc.’s income before income taxes as a percentage of revenues decreased from 2018 to 2019 but then increased from 2019 to 2020 exceeding 2018 level. |
Net income | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | Regeneron Pharmaceuticals Inc.’s net income as a percentage of revenues decreased from 2018 to 2019 but then increased from 2019 to 2020 exceeding 2018 level. |